Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That $40M is probably half that. Company has to prepare to delist or worse, bankruptcy. The notice is a week away.
Corporate investors who have to be paid back will be the first to dump everything to get their investment repaid before suing SBFM along with penalties from being non compliant with NASDAQ and unable to convert warrants to $4.25 a share.
That $40M has to be paid back one way or another, and SBFM does that by using dilution and retail share holders.
That PPT they released was to save their ass with a new round of investors and look how well that worked.
Market cap is hovering between $12-14M and falling.
Danger Will Robinson. This scam hasn’t addressed anything and there is no reason to believe it can recover. Shareholder communications is nonexistent, why would anyone loan this company more money when it went from $8 to $0.65 in less then a year and they have released no PR’s, self promoted or paid articles for nearly 2 months now.
Even the market agrees and they have corporate hedgers shorting and registered the short with a 13F because SBFM is a worthless shell and have nothing of value.
Pumpers would be all over this but they aren’t. This scam may be frozen, suspended, investigated and audited.
The claims they made mostly regarding SBFM-PL4 (Covid) probably got them on a watchlist.
You mean next April … hope we don’t see delisting on April fool’s day
I am curious what are they doing with that 44m
So looks like will have a better clue about the future of SBFM in 3-5 months. Either still on the path to delisting or a comeback with significant progress reported on cancer and covid treatments!
The PPS went under $1 on Sept 14, so they'll get their notice from NASDAQ next week. That will give them 180 days to comply. If, after that 180 days, they're still below $1, they can get another 180 days, but will have to submit a plan to become compliant, meaning they'd likely commit to doing a RS.
Also: explain to me the logic of staying silent when the SP is plummeting?? Like what is the strategy?
You seem to be unconcerned about delisting even though the SP is at .69.
Is a RS on the table or been discussed?
Are you planning on applying for an extension to keep from getting delisted?
I hope the answer is not RS grrr
Someone else could also call. I don’t think I’d be his favorite person. The best question I can think of is pretty much this:
What’s going on with your share price and what are you doing about it?
I didn’t realize yesterday was also a Holiday for Canada. Hah. Ok so I called again and got a hold of Camille and hung up. Really didn’t expect him to answer and my head went blank.
I’ll try again. Haha. What should I ask?
.688 = .0034
Why is every OTC stock a scam. Oh I forgot this is a Nasdaq stock but still a scam!
If they get delisting notice… hope there is no RS
Look like ever week is a New Low
I’m surprised the number is still hooked up
I called 5144266161 and it goes to VM after a recorded message in French.
So we’re around 23 days now and no response?
I wonder who is answering Sunshine BioPharma?
The same number used to forward directly to Camille’s cell phone.
Latest institutional investors (all have value of 0 or about 300 or less shares)
Investor Name Shares Changed Value
1) Larson Financial Group LLC 127 0 0.0000
2) Proequities, Inc. 0 0 0.0000
3) Citigroup Inc 130 0 0.0000
4) UBS Group AG 1 99.96 -100.00
5) Signaturefd, Llc 300 0.00 -100.00
6) Empery Asset Management, LP 0 -100.00 -100.00
7) Hudson Bay Capital Management LP 0 -100.00 -100.00
8) Armistice Capital, Llc 0 -100.00 -100.00
9) Jane Street Group, Llc 0 -100.00 -100.00
10) Blackstone Alternative Short -45
SBFM’s adva-27a treats breast, pancreatic, and ovarian cancer in this PR:
https://www.globenewswire.com/en/news-release/2022/04/05/2416581/35334/en/Sunshine-Biopharma-s-Newly-Designed-mRNA-Molecules-Prove-Effective-Against-Multidrug-Resistant-Cancer-Cells.html
Lung, uterine, and more cancer here:
https://sunshinebiopharma.com/anticancer-drugs/
Sunshine BioPharma’s Flagship Anticancer Drug adva-27a is effective at killing different types of multidrug resistant cancer cells, and other types including:
* Breast Cancer Cells (MCF-7/MDR)
* Small Cell Lung Cancer Cells (H69AR)
* Uterine Cancer (MES-SA/Dx5)
* Pancreatic Cancer (Panc-1)
Link: https://sunshinebiopharma.com/anticancer-drugs/
Remember Ebola? It treats that too:
https://www.outsourcedpharma.com/doc/lonza-to-manufacture-sunshine-biopharma-s-anti-cancer-compound-0001
As well as many other types of cancer scattered over the last 10-12 years of PRs.
Seems like rat poison or a wonder drug. If it was really so great, why didn’t it get FDA approval?
This post was interesting from RB Cap.
From Brett’s point of view, he was just doing his job as a loan shark. Loaned a bad company money that would pay him back many many many times more because no one else would.
Sunshine used RB Cap to raise money, and Sunshine used shareholders (dilution and stock shares, etc) to pay RB Cap back with exceptionally high interest. This is how loan sharks aka hard money lenders do business when nobody else will give you cash.
All I can think of is that they went quiet for obvious reasons.
10-Q will be out soon since 9-30 accounting period has closed.
I looked at twitter a while ago and it’s nothing but a sh1te storm.
Why they wouldn’t say or release something or anything is beyond me unless of course..
I contacted some ‘stutes but only RB Cap and Fidelity responded.
Fidelity still had SBFM listed as of 8/31 in their NASDAQ index fund.
Brett and RB cap I don’t know but I think about 6 months ago Brett mentioned he still had a small position invested. He’s suing $OPTI, don’t know what he’s up to with SBFM.
Slilaty Camille … no single word on PL4 ? Investors sure do have oxidative stress but thankfully don’t have Alzheimer’s yet ?
Any update on that age old pl4 ?
Adva-27a is 2032/3 in USA (patent exp).
They filed it in other countries but it has to get approval at least somewhere. To date, no progress.
If SBFM was not successful 10 years, especially saying it would be the best on the market, why do it again 10 years LATER with adva-27a?
Might be another 10-15 years because nothing ever started.
That 10-15 year timeline generally is for BigPharma and doesn’t really make sense for someone as small as SBFM who can’t even manufacture vitamin C because they have no pharmaceutical plant and have to buy vitamins or anything from a outside supplier.
Same with SBFM-PL-4. It was filed in 2020 but zero update on its status at the FDA and patent office, so where is it? Did it get denied?
K1.1 has a provisional patent date of 2022, but it’s like starting all over again, another 10-15 year wait. Same exact thing, we filed.
WHAT IS THE STATUS with the FDA and US Patent filing? What's the filing numbers? Nobody has ever seen anything except "we filed.". Yes, anyone can file! Most don't ever get approved. And what was that weird SEC exchange with Slilaty with a file number located here:
https://www.sec.gov/Archives/edgar/data/1402328/000000000022005515/filename1.pdf
Steve Slilaty
Chief Executive Officer
Sunshine Biopharma, Inc
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
Re: Sunshine Biopharma, Inc
Registration Statement on Form S-3
Filed May 10, 2022
File No. 333-264830
Dear Dr. Slilaty:
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alyssa Wall at 202-551-8106 with any questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc: Jeff Cahlon
It all depends on approval which they never got for ANYTHING from the FDA.
What worries me is if SBFM does delist, I think all the SBFMW warrants become worthless because they cannot be exercised at $4.25 if there is no NASDAQ ticker called SBFM. I’ve never seen this happen before and don’t know the answer.
Then they have to get to do this if they ever get anything approved:
Clinical stage 1 (this would be huge)
Clinical Stage 2 (even better)
Clinical Stage 3 (this would be great but even so we are looking at 10% as compared to BigPharma with same timelines)
Get the FDA and patent approval and I may change my mind, but then there’s the 10-15 year wait……..And 90% chance of a failure or side effects and it’s back to the drawing board to correct it and start the process all over again)
By the time they start phase1, which is always 18-24months, only Dr Shitty knows from which date, patent will run out, but most likely scenario is company will go under in year or so and Dr Shitty and company enjoying on some tropical beach .
I’ve asked around but nobody has an answer to this. What happens to shares of SBFMW if/when SBFM can’t stay above $1 and gets delisted? Each share can be exercised 1:1 at $4.25 according to their PR. But what good is it if SBFM doesn’t tick on NASDAQ? It’s in this PR:
https://www.globenewswire.com/en/news-release/2022/02/15/2385396/35334/en/Sunshine-Biopharma-Inc-Announces-Pricing-of-8-Million-Public-Offering-and-Uplisting-to-the-Nasdaq-Capital-Market.html
Nope. Not in quite some time. Nor have I tried but he did answer when I called or emailed.
Have you tried calling Camille recently? Is not there anymore??
I believed too. Worse.. I broke my rule and brought my partner in. I did deep research from European origins to initial shell structure and corporate structure attempts that were denied. I got out almost even but partner got attached to hope. It did not end well for her.
Ugh. Live and learn.
I believed in this company and even spoke with Camille. It’s really disappointing. Everyone must have left or something. Crickets
As of August 31, I was able to verify Fidelity FNCMX which is a nasdaq index fund still carries SBFM even though it’s sub $1.
They are listed as an institutional investor.
Don’t know about September or this month.
Unless an institutional investor takes out a long short such as Blackstone did and reported it, all these institutional shorts are hedging huge to short this.
Market sentiment is this won’t recover if it’s literally being shorted at $35-45 a share.
If I understand correctly, a 1000 share short would cost about $40,000 @ a $40 avg short share price.
But the profits are huge and it goes unreported as a Darkpool short IF it was covered same day, which results in a big sell off, and then a cover and pocket the difference.
If it’s not, my understanding is that what generates a FTD?
A healthy stock can have 1 to 7 days or longer to cover. Not less than one day.
This is kind of interesting, shorts have to cover every day as the cover period is less than 1 day. Not entirely sure how this is interpreted under short sales (FTD).
Does it mean they covered after 1 day and profited that amount? Each share I think cost about $35-45 to short, if I'm understanding this correctly.
Date Price Quantity Value
2022-08-09 1.31 104,690 $137,143.90
2022-07-28 1.25 104,084 $130,105.00
Short Shares Availability
This table shows the number of shares of US:SBFM available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
It does not include data from other brokers or dark pools. It is a small sample, and it is useful for tracking the rise and fall in demand for shares throughout the day and weeks. It should not be treated as an absolute number of shares that are available to short in the market.
We update our database every 30 minutes but only display changes, in order to improve readability.
Update Frequency: Intraday
Last update: 2 minutes ago
Time Since
Last Change Timestamp (UTC) US:SBFM Short Shares Availability
6 hours ago 2022-10-05 11:16:47.994 400,000
1 day ago 2022-10-04 15:27:23.113 600,000
1 day ago 2022-10-04 06:24:14.681 400,000
1 day ago 2022-10-04 04:18:55.73 250,000
2 days ago 2022-10-03 11:34:40.15 400,000
2 days ago 2022-10-03 10:01:23.623 600,000
5 days ago 2022-09-30 15:16:58.802 550,000
5 days ago 2022-09-30 11:38:52.816 400,000
5 days ago 2022-09-30 10:34:46.021 550,000
5 days ago 2022-09-30 10:02:15.923 350,000
Short Borrow Fee Rates
SBFM / Sunshine Biopharma, Inc. short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:SBFM to the lender of that security. This fee is shown as an annual percentage rate (APR). Lenders are funds or individuals that own the security that have indicated to the broker that they are willing to lend it out. Dividends paid to a shorted security go to the owner/lender of the security, not to the borrower.
Start, Min, Max, Latest (Borrow Rates)
These represent borrow rates for the day, with the rate at the start of the day, the end of the day (or the latest for the current day), the minimum rate in the day, and the maximum rate for the day. Unlike the Options Implied Borrow Rates, our source for this data always presents them as positive numbers, and they represent an annualized interest rate that is paid by the borrower for the shares.
Update Frequency: Intraday every 30 minutes.
Last update: 2 minutes ago
Date Start Min Max Latest
2022-10-05 36.51 36.51 37.42 37.18
2022-10-04 36.89 36.49 36.89 36.51
2022-10-03 36.80 36.80 36.89 36.89
2022-09-30 37.24 36.77 37.24 36.80
2022-09-29 37.23 37.23 37.24 37.24
2022-09-28 37.22 37.22 37.23 37.23
2022-09-27 33.41 33.41 37.22 37.22
2022-09-26 38.23 33.41 45.80 33.41
2022-09-23 45.80 38.23 45.80 38.23
2022-09-22 45.92 45.80 45.92 45.80See companies with highest Short Borrow Fee Rate
Short Sale Volume (Off-Exchange Provided by FINRA)
SBFM / Sunshine Biopharma, Inc. off-exchange short sale volume is shown in the following chart. Short Sale volume shows the number of trades marked as short sales in various trading venues. For more information on how to interpret this data, read this information notice provided by FINRA.
Update Frequency: Daily at Close of Day
FINRA Non-Exempt Volume
Number of short shares traded. This number is not provided by FINRA but we calculate it by subtracting the "Exempt" from the "Short Volume"
FINRA Exempt Volume
Number of short shares sold that were exempt from the uptick rule. This is provided by FINRA. This number is included in both the "Short Volume" and "Total Volume" numbers.
FINRA Short Volume
Number of short shares traded reported by FINRA. This includes both the exempt and non-exempt.
Market Date Non-Exempt Volume Exempt Volume Short Volume Total Volume Short Volume Ratio
2022-10-04 17,699 + 442 = 18,141 / 43,865 = 41.36
2022-10-03 96,245 + 0 = 96,245 / 135,189 = 71.19
2022-09-30 40,361 + 385 = 40,746 / 81,646 = 49.91
2022-09-29 27,824 + 0 = 27,824 / 65,439 = 42.52
2022-09-28 24,744 + 2,600 = 27,344 / 69,047 = 39.60
2022-09-27 87,718 + 0 = 87,718 / 138,556 = 63.31
2022-09-26 83,132 + 1,370 = 84,502 / 183,236 = 46.12
2022-09-23 87,568 + 1,350 = 88,918 / 146,469 = 60.71
2022-09-22 135,971 + 12,457 = 148,428 / 342,707 = 43.31
2022-09-21 110,124 + 1,721 = 111,845 / 270,183 = 41.40
Short Sale Volume (Combined Exchange + Off-Exchange )
The combined on-exchange and off-exchange short sale volume for SBFM / Sunshine Biopharma, Inc. is provided in the table below. In order to calculate an accurate short volume ratio, we gather data from a number of trading venues, but not ALL trading venues. This is important because it means the aggregate short and total volume columns do not show the actual volumes across all trading venues, but just the venues we track.
Market Date FINRA
Short Volume CBOE
Short Volume PSX/BX
Short Volume Aggregate
Short Volume * Aggregate
Total Volume * Aggregate
Short Volume Ratio
2022-10-04 18,141 + 5,627 + = / =
2022-10-03 96,245 + 11,162 + 100 = 107,507 / 151,122 = 71.14
2022-09-30 40,746 + 15,352 + = / =
2022-09-29 27,824 + 5,979 + = / =
2022-09-28 27,344 + 2,971 + = / =
2022-09-27 87,718 + 2,605 + = / =
2022-09-26 84,502 + 11,736 + 0 = 96,238 / 201,177 = 47.84
2022-09-23 88,918 + 8,943 + 600 = 98,461 / 165,753 = 59.40
2022-09-22 148,428 + 29,784 + 0 = 178,212 / 408,728 = 43.60
2022-09-21 111,845 + 58,235 + 100 = 170,180 / 341,942 = 49.77Find more short volume data here.
Fails-To-Deliver
The values of total fails-to-deliver shares represent the aggregate net balance of shares that failed to be delivered as of a particular settlement date. Fails to deliver on a given day are a cumulative number of all fails outstanding until that day, plus new fails that occur that day, less fails that settle that day. The figure is not a daily amount of fails, but a combined figure that includes both new fails on the reporting day as well as existing fails. In other words, these numbers reflect aggregate fails as of a specific point in time, and may have little or no relationship to yesterday's aggregate fails. Thus, it is important to note that the age of fails cannot be determined by looking at these numbers. If all shares were delivered on a particular day, then there will be no entry in the table.
Update Frequency: SEC publishes daily data in batches that are delivered twice monthly and lagged about two weeks. So, for example, daily data for the month of March would arrive on our around mid April.
SBFM / Sunshine Biopharma, Inc. Fails-To-Deliver
Date Price Quantity Value
2022-09-06 1.08 6,521 7,042.68
2022-08-31 1.10 412 453.20
2022-08-17 1.28 93 119.04
2022-08-12 1.24 17,718 21,970.32
2022-08-11 1.23 29,524 36,314.52
2022-08-10 1.24 36,186 44,870.64
2022-08-09 1.31 104,690 137,143.90
2022-08-08 1.27 19,538 24,813.26
2022-08-02 1.09 29,662 32,331.58
2022-08-01 1.08 3,957 4,273.56
2022-07-29 1.15 3,228 3,712.20
2022-07-28 1.25 104,084 130,105.00
2022-07-27 1.36 4,166 5,665.76
2022-07-26 1.03 34,239 35,266.17
2022-07-25 1.05 267 280.35
2022-07-19 1.09 47 51.23
2022-07-18 1.13 2,064 2,332.32
2022-07-14 1.14 3,616 4,122.24
2022-07-12 1.14 107 121.98
2022-07-11 1.18 13,301 15,695.18
Short Interest
Short Interest is the total number of open short positions of a security. A Short Squeeze is when a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest by purchasing actual shares, which in turn drives the price up even further.
Update Frequency: Twice Monthly
SBFM / Sunshine Biopharma, Inc. Short Interest
Date Short Interest Days to Cover
2022-09-15 108,189 1.00
2022-08-31 396,064 1.19
2022-08-15 590,649 1.00
2022-07-29 491,584 1.00
2022-07-15 66,269 1.00
2022-06-30 76,155 1.00
2022-06-15 116,634 1.00
2022-05-31 195,681 1.00
2022-05-13 830,539 1.00
2022-04-29 628,379 1.00
2022-04-14 1,150,480 1.00
2022-03-31 152,306 1.00
2022-03-15 445,458 1.00
2022-02-28 50,561 1.00
2022-02-15 8,085 1.00
2022-01-14 91,581 1.00
2021-12-31 26,423 1.00
2021-12-15 3,800 1.00
2021-11-30 32,668 1.00
2021-11-15 14,862 1.00
2021-10-29 54 1.00
2021-10-15 54 1.00
Latest fintel. Interesting that directors have about $10 worth of stock or less and Camille shows a 13% gain profit.
Insider Title Symbol Latest Filing Shares Split Adjusted
Shares
TELSEY ANDREW I Director SBFM 2021-12-09 3,000 15
Slilaty Steve N. CEO SBFM 2022-02-22 10,000 10,000
Sebaaly Camille CFO/Secretary SBFM 2022-06-06 144,465 144,465
NATAN DAVID Director SBFM 2022-02-18 0 0
MERZOUKI ABDERRAZZAK COO SBFM 2021-02-16 23,342,500 116,712
Kish James Daniel Director SBFM 2021-12-14 2,500 12
Kiderchah Rabi Director SBFM 2021-12-16 325,000 1,625
Keller Andrew Mark Director SBFM 2022-02-18 0 0
Advanomics Corp 10% Owner SBFM 2016-11-07 215,014,224 2,687,678
Can’t see any updates or changes for SBFM, looks like it’s running on fumes or short coverage imo.
Could go back down, this has not any support in L-II
Good time for SBFM to seize the moment and release something otherwise it’s just going up on fumes and will likely collapse again.
I contacted a few, such as the people who did the billion dollar audit for SBFM but never got a response or call back. RB cap or Brett Rosen did.
Be interesting to see if anyone does say anything, from the universities to institutions that decided to leave or short SBFM.
Studies could be held under NDA. Not sure until someone calls or contacts them
I wonder if someone called the two research colleges and asked about if sbfm was still working with them . The answer you would get is …… who ??? Very sorry indeed what has happened here.
Ridiculous… they have no qualms for that 10m separation deal … when mc is hardly 16-17m
10m for what ? What was given back in return ? Which dollars fund that 10m?
Pls correct me if my 10m understanding is not correct
Yeah. It’s going to get worse. The company has not ever been this quiet nor has it released any type of PR, sponsored, promo or anything else. No response after saying they were being #transparent 3-4 mos ago except a power point presentation to attract more investors and money. Cmon!!!!
It’s going to be really interesting to see their end of month quarterly for August and September, I think that’s when s hit the fan after people got fed up with 90-99% losses year after year after year.
If they stay on this path and more institutional and retail investors leave, it’s not recoverable imo.
Even if they tried, they could perhaps stave it off, but it looks like they are not even trying. #NoHope
A share buy back would deplete part of whatever is left of their millions in the bank which is most likely allocated to other things, such as their $8M IPO offering. Do they have to pay that back if they get booted from nasdaq? I don’t know the answer to that.
A reverse split to stay uplisted is just another red flag to all investors. We all know what that means.
I’d be concerned about if they have anymore convertible debt or other convertible debt by hard money loan sharks. That will likely either result in more shareholder dilution or hard cash, which they have apparently never used to improve shareholder communications or increase share price.
It’s seem their motto is just to enrich themselves and screw investors because every thing they’ve put out has a disclaimer saying it’s all subject to change and dependent on these bogus filings that they *ALWAYS* anticipate being approved.
Pretty much the only thing that was approved was adva-27a, which has been bouncing from corp to corp to corp because it’s not safe on humans. You have to get approval and go to stage 1, 2, and then 3, which takes 10-15 years for Big Pharma, not 3 people who work out of a fake virtual office for $300 a month with a business line that forwards to Camille’s expensed cell phone that investors pay for.
Terrible what happened here jmo
I believe more institutional/retail investors
have left or decreased holdings like UBS (they sold all but 1 share). Empery unloaded $1.10 million, filed their exit form for SBFM and some nut job PR’d that Empery had just invested that amount after they left!! That’s just messed up.
US8677814035 Institutional Ownership and Shareholders - Sunshine Biopharma Inc
Institutional Owners 18 total, 17 long only, 1 short only, 0 long/short - change of 50.00% MRQ
Average Portfolio Allocation 0.0473% - change of -98.18% MRQ
This is not a question of if, it's a question of when! Load up while the weak sell.
I agree, six months to load? Pass or fail, this is an opportunity.
Is Roy Toy sailing the 7 seas yet? lol
How about in 7 weeks, 7 months, 7 years, 7 decades? NOT
Some keep on giving away their shares for cheap and I keep on loading up. I'm loving it! Keep it up!
Agreed. Hate to say it. Very disappointing.
iluvcanada sniffed out this company 4-5 years ago. Outrun, thanks for posting this. Wonder if he is still around. A lot of the posts from 2018 show how SBFM has used the market as a washing machine since their inception. Don't need an 8-ball here to predict the future. SBFM had that 10-K blunder a couple years back which lit up Camille's phone due to accounting errors and other issues and had to issue an amended 10-K (10-K/A) to make their investors happy.
SBFM blundered their first attempt to uplist and gave up, and the second time, they did succeed, but look where we're at with this stock. They file for patents left and right and immediately PR them, along with FDA filings, and immediately tell the world "We've filed for FDA Fast tracking and Patent Priority" and never follow up with that. That's great, I'm going to PR the world that I mailed a letter or filed online and then put out a Press Release.
Anyone can literally file. SBFM-PL4 was exempt from fees with the FDA and patent office because it was marketed as a COVID treatment. No fees, no red tape, and then based the entire future of the company on filings that were never accepted, rejected, incomplete, etc, etc, with the intent to abandon these things all together because they didn't actually get the patents or FDA approvals. This is the stuff SBFM *NEVER* PR's. Only the fluff crap that they mailed a letter to the FDA and patent office and expect to cure pancreatic cancer as of the last power point.
adva-27a was labeled as a treatment for breast cancer, lung cancer, and other types of cancer (basically it just seems to kill everything). The latest powerpoint says it is now for pancreatic cancer.
SBFM-PL4 was stated as killing every variant of covid from Covid-19 to Covid-29. Really, wow! Yet they push vitamins and adva-27a that will expire before it ever gets to market, and if it did, it'll be a generic that anyone can copy. adva-27a is not marketable. If it was really worth a billion bucks, SBFM would have sold it to anyone willing to buy it. Instead, the only people interested were micro stock investors.
They're going to drop adva-27a and start the timelines all over with K1.1, which looks like it is some re-incarnated variant of adva-27a and SBFM-PL4:
"
Anticancer K1.1 mRNA
K1.1 is an mRNA that encodes an inhibitor of a transcription factor essential for initiation of cell division
We have recently shown that K1.1 mRNA is capable of destroying cancer cells in vitro including breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2)
Tests conducted using non-transformed (normal) cells (HMEC) showed that these K1.1 mRNA had little cytotoxic effects
K1.1 mRNA is readily adaptable for delivery into patients using the mRNA vaccine technology
In April 2022, we filed a provisional patent application in the United States covering the K1.1 mRNA molecules and uses thereof
Next, we plan to conduct mice xenograft studies to test the efficacy of K1.1 mRNA in vivo
"
It just never ends. I really wonder what the quarterly is going to say and project. Anyone who is still left is waiting on that before they get the hell out or the next pump before the next group of investors moves in and doesn't realize what a mess this company is.
Link to message: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140206966
From: iluvcanada
Re: Jagz16 post# 37528
Friday, April 20, 2018 4:29:07 PM
Post # 37529 of 111993
It's a pinky scam, just like so many others.....if you are even close to a profit or are even, SELL!!!! get the hell out of this garbage!
This isn't a company. It's a shell. It's a scam designed to make a few scumbags in Canada money. Not to mention, I can't verify or validate one thing they have ever accomplished. Not one. No drug license, no labs, no workers, no agreements, no valuation, no generics, and I'm pretty sure they mentioned in their last filing that ADVA-27a (which is not a real drug, nor will it ever be), was given to a company they started in Colorado (NOX Pharma). I doubt the purchase of Atlas ever took place. If it did, they used SBFM money to pay for it, and will privately benefit from it.
No shareholders will see any value added, just more dilution. Same thing happened with the purchase of the patents....investors paid for those, that money went directly to Advanomics, an address, not even a company that is owned by the same people. So we bought rights to Adva from this management teams personal business for millions, after Advanomics bought it from a French company for about 60K. SCAM.
Now it's reading like all that money investors used to buy the worthless patents is being given to a Colorado based company known as: NOX Pharma, which these morons own too. Not sure if it will one day be public, or maybe the gave the patents back to themselves for free, after raping SBFM investors.
https://www.sos.state.co.us/biz/BusinessEntityDetail.do?quitButtonDestination=BusinessEntityResults&nameTyp=ENT&masterFileId=20181234726&entityId2=20181234726&fileId=20181234726&srchTyp=ENTITY
https://www.sos.state.co.us/biz/ViewImage.do?masterFileId=20181234726&fileId=20181234726
I can go on and on and on......it's just another penny scam. That's the theme here. These guys just go further than most, to scam you out of your money.
If none of that convinces anyone, just read their last quarterly, it's beyond pathetic. Expect a bankruptcy filing soon, lay SBFM to rest, and start over with: NOX Pharma....... Why else start a new company and give it Adva-27a?
--
link: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139299109
From: iluvcanada
Re: None
Wednesday, March 14, 2018 9:45:45 PM
Post # 37506 of 111993
Anyone heard from(Camille) lately? Anyone tried calling or emailing? Or are we still running on their "word" on things?
This is why no one believes anything will happen this year. Or ever....
In November 2014, we entered into a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly referred to as “Lonza”), whereby we engaged Lonza to be the manufacturer of our Adva-27a anticancer drug. In June 2015 we received a sample of the pilot manufacturing run for evaluation. Our laboratory analyses showed that, while the sample meets the required biological specifications, the amount of material generated (the “Yield”) by the pilot run was found to be significantly lower than planned. During the course of our discussions concerning the problem of the low Yield, Lonza informed us that they required us to pay them $687,818 prior to moving forward with any activity pertaining to the manufacturing agreement we have with them. We have repeatedly indicated to Lonza that a clear path defining exactly how the extremely low Yield issue would be addressed is imperative prior to us making any payments. As of the date of this report, neither party has changed its position. See “Part I, Item 3 – Legal Proceedings.”
Keeping in mind, none of that is verifiable. Lonza won't comment, no one knows if any of that actually happened. That is a huge amount of money they are requesting. These idiots don't have that. They could have used the money they stole from investors for the patents they sold to themselves to fund this, but no one knows where that patent money went. If this was a billion dollar drug (Adva-27a), or you had actual leadership that believed in the drug, they would spend every cent they had to get it to market. There is no drug, there is no plan. SBFM is their own personal bank, nothing more. At this point, I'd accept them diluting this stock to fund another batch of the drug, at least it shows initiative and belief in the product. According to these scam artists, it's so much better than what's currently out there....why not dilute the stock to fund a new batch, rather than buy Atlas Pharma?
May the retirement happen by making History not just by age
Followers
|
761
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
113741
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
SUNSHINE BIOPHARMA INC
ANTI CANCER DRUGS
ANTI CORONA VIRUS RESEARCH
SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 - 5800 f
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |